Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.
Abstract
The inhaled, long-acting muscarinic antagonist, aclidinium bromide, was indicated in July 2012 in Europe and the USA for the maintenance of bronchodilator treatment to relieve symptoms of chronic obstructive pulmonary disease (COPD) in adults. Although initially investigated as a once-daily agent, a lower than expected improvement in trough forced expiratory volume over 1 s prompted re-evaluation as a twice-daily (b.i.d.) regimen. The dose approved for use in Europe, 400 μg b.i.d., achieved statistically significant improvements in lung function, reductions in breathlessness, and improved health-...
Source: Advances in Therapy - April 1, 2013 Category: Drugs & Pharmacology Authors: Jones P Tags: Adv Ther Source Type: research
